<DOC>
	<DOCNO>NCT01150630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride , cisplatin , epirubicin hydrochloride , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving gemcitabine hydrochloride , without cisplatin , epirubicin hydrochloride , capecitabine surgery may make tumor small reduce amount normal tissue need remove . Giving drug surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase II/III trial study well gemcitabine hydrochloride , without cisplatin , epirubicin hydrochloride , capecitabine , work give and/or surgery treating patient stage I stage II pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Epirubicin , Capecitabine Treating Patients With Stage I-II Resectable Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess proportion patient event-free ( defined disease progression , local recurrence , distant metastasis , new tumor , death ) 1 year neoadjuvant therapy comprise gemcitabine hydrochloride cisplatin , epirubicin hydrochloride , capecitabine ( PEXG ) , adjuvant chemotherapy comprise gemcitabine hydrochloride PEXG regimen patient resectable stage I II adenocarcinoma pancreas . ( phase II ) - To assess whether best experimental regimen , select basis phase II part trial , able improve overall survival compare standard adjuvant gemcitabine patient . ( phase III ) Secondary - To assess radiological , biochemical , pathological response rate ( neoadjuvant arm ) patient . - To assess surgical resection rate , surgical mortality morbidity , proportion patient negative surgical margin . - To assess lymph node status patient . - To determine tolerability regimens patient . OUTLINE : This multicenter study . Patients stratify accord center . Patients randomize 1 3 treatment arm . - Arm I ( adjuvant gemcitabine hydrochloride ) : Patients receive gemcitabine hydrochloride IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day 6 month absence disease progression unacceptable toxicity . - Arm II ( adjuvant cisplatin , epirubicin hydrochloride , gemcitabine hydrochloride , capecitabine [ PEXG regimen ] ) : Patients receive cisplatin IV 1 hour day 1-5 , epirubicin hydrochloride IV day 1 8 , gemcitabine hydrochloride IV 1 hour day 1 8 , oral capecitabine day 1-14 . Treatment repeat every 14 day 6 month absence disease progression unacceptable toxicity . - Arm III ( neoadjuvant adjuvant PEXG regimen ) : Patients receive neoadjuvant cisplatin IV 1 hour day 1-5 , epirubicin hydrochloride IV day 1 8 , gemcitabine hydrochloride IV 1 hour day 1 8 , oral capecitabine day 1-14 . Treatment repeat every 14 day 3 month . Patients undergo surgery pancreatic cancer follow adjuvant ( within 2 month surgery ) PEXG give neoadjuvant therapy . Treatment adjuvant PEXG repeat every 14 day 3 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 4 month 2 year , every 6 month thereafter .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically* confirm adenocarcinoma pancreas Stage III disease Resectable disease No superior mesenteric vein artery , portal vein , celiac trunk , hepatic artery infiltration No symptomatic duodenal stenosis NOTE : Patients without histological cytological result may allow provide ≥ 1 attempt make needle aspiration negative image clinical sign suggestive adenocarcinoma . PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % WBC ≥ 3,500/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.5 mg/dL ALT AST ≤ 3 time upper limit normal Bilirubin ≤ 3 mg/dL No prior concurrent malignancy within past 5 year except surgically cure carcinoma situ cervix basal cell squamous cell carcinoma skin Not pregnant nursing No psychological , familial , sociological , geographical condition would potentially hinder study compliance followup schedule PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy pancreatic adenocarcinoma No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>